Celcuity shares surge 13% on Phase 3 trial results; 20 stocks moving in pre-market trading.

Celcuity shares rose 12.6% in pre-market trading after announcing topline results from the Phase 3 VIKTORIA-1 trial. Other gainers include CEA Industries, Mill City Ventures, and Anghami, while losers include Sidus Space, 180 Life Sciences, and Zooz Power.

Celcuity Inc. (NASDAQ:CELC) shares surged 12.6% in pre-market trading on July 2, 2025, following the announcement of topline results from the Phase 3 VIKTORIA-1 trial. The trial, which evaluated gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer, showed promising results that have significantly boosted investor confidence in the company's oncology pipeline [1].

The Minneapolis-based biotechnology company will host a conference call and webcast on July 28, 2025, at 8:00 AM ET to discuss the trial outcomes in detail. Analysts maintain a strong buy consensus on Celcuity stock, with price targets ranging from $27 to $33, reflecting the optimism around the potential of gedatolisib as a standard-of-care treatment in the metastatic breast cancer landscape [2].

Gedatolisib, Celcuity's lead therapeutic candidate, is a pan-PI3K and mTORC1/2 inhibitor that blocks the PAM pathway, differentiating itself from other approved and investigational therapies targeting similar pathways. The company's Phase 3 clinical trials, VIKTORIA-1 and VIKTORIA-2, aim to establish gedatolisib as a first-line treatment option for HR+/HER2- advanced breast cancer patients [3].

The positive pre-market reaction to the VIKTORIA-1 trial results underscores the market's belief in Celcuity's ability to deliver innovative cancer treatments. The company's stock price increase also comes amid a broader market environment where other gainers include CEA Industries, Mill City Ventures, and Anghami, while losers include Sidus Space, 180 Life Sciences, and Zooz Power.

References:
[1] https://www.stocktitan.net/news/CELC/celcuity-to-announce-topline-results-for-the-pik3ca-wild-type-cohort-1zd03ouzao4t.html
[2] https://www.investing.com/news/company-news/celcuity-to-announce-phase-3-viktoria1-trial-results-on-monday-93CH-4153939
[3] https://www.investing.com/news/stock-market-news/celcuity-stock-jumps-ahead-of-pivotal-breast-cancer-trial-results-93CH-4153899